Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
The present invention provides compositions comprising retroviral vectors, transduced cells, and methods of using the same for gene therapy. In particular, the present invention relates to lentiviral vectors and cells transduced with those vectors to provide gene therapy to subjects having an adrenoleukodystrophy and/or adrenomyeloneuropathy.
1. A vector comprising from 5′ to 3′:
(a) a left (5′) retroviral LTR;
(b) a central polypurine tract/DNA flap (cPPT/FLAP);
(c) a retroviral export element;
(d) a promoter active in a microglial cell, operably linked to a polynucleotide encoding an ATP-binding cassette, sub-family D, member 1 (ABCD1) polypeptide; and
(e) a right (3′) retroviral LTR;
wherein the vector does not comprise a post-transcriptional regulatory element.
2. The vector of claim 1 , wherein the vector is a lentivirus vector.
3. The vector of claim 2 , wherein the lentivirus is HIV.
4. The vector of claim 2 , wherein the lentivirus is HIV-1.
5. The vector of claim 1 , wherein the promoter of the 5′ LTR is replaced with a heterologous promoter selected from the group consisting of: a cytomegalovirus (CMV) promoter, a Rous Sarcoma Virus (RSV) promoter, or an Simian Virus 40 (SV40) promoter.
6. The vector of claim 1 , wherein the 3′ LTR is a self-inactivating (SIN) LTR.
7. The vector of claim 1 , wherein the promoter active in a microglial cell comprises a myeloproliferative sarcoma virus enhancer, negative control region deleted, d1587rev primer-binding site substituted (MND) promoter or transcriptionally active fragment thereof.
8. The vector of claim 1 , wherein the polynucleotide encoding the ABCD1 polypeptide is a cDNA.
9. The vector of claim 8 , wherein the cDNA comprises an optimized Kozak sequence.
10. A lentiviral vector comprising from 5′ to 3′:
(a) a left (5′) LTR;
(b) a cPPT/FLAP;
(c) an RRE;
(d) a MND promoter operably linked to a polynucleotide encoding a human ABCD1 polypeptide;
(e) a right (3′) LTR; and
(f) a polyadenylation sequence;
wherein the vector does not comprise a post-transcriptional regulatory element.
11. The lentiviral vector of claim 10 , further comprising a Psi (Ψ) packaging signal.
12. The lentiviral vector of claim 10 , wherein the polyadenylation sequence is a bovine growth hormone polyadenylation signal or a rabbit β-globin polyadenylation sequence.
13. A lentiviral vector comprising from 5′ to 3′:
(a) a left (5′) HIV-1 LTR;
(b) a Psi (Ψ) packaging signal;
(c) a cPPT/FLAP;
(d) an RRE;
(e) a MND promoter, operably linked to a cDNA encoding a human ABCD1 polypeptide;
(f) a right (3′) self-inactivating (SIN) HIV-1 LTR; and
(g) a rabbit β-globin polyadenylation sequence;
wherein the vector does not comprise a post transcriptional regulatory element.
14. A vector comprising from 5′ to 3′:
(a) a left (5′) retroviral LTR;
(b) a central polypurine tract/DNA flap (cPPT/FLAP);
(c) a retroviral export element;
(d) a promoter active in a microglial cell, operably linked to a polynucleotide encoding an ATP-binding cassette, sub-family D, member 1 (ABCD1) polypeptide;
(e) a right (3′) retroviral LTR;
(f) a polyadenylation (polyA) sequence; and
wherein the vector does not comprise post-transcriptional regulatory element.
15. A lentiviral vector comprising from 5′ to 3′:
(a) a left (5′) HIV-1 LTR;
(b) a Psi (Ψ) packaging signal;
(c) a cPPT/FLAP;
(d) an RRE;
(e) a MND promoter, operably linked to a cDNA encoding a human ABCD1 polypeptide;
(f) a right (3′) self-inactivating (SIN) HIV-1 LTR; and
(g) a polyadenylation (polyA) sequence;
wherein the vector does not comprise post-transcriptional regulatory element.
16. A mammalian cell comprising a vector according to any one of claims 1 , 10 , 13 , 14 and 15 .
17. A producer cell comprising: a first polynucleotide encoding gag, a second polynucleotide encoding pol, a third polynucleotide encoding env, and a vector according to any one of claims 1 , 10 , 13 , 14 and 15 .
18. A vector particle comprising a vector according to any one of claims 1 , 10 , 13 , 14 , and 15 .